



KENNY C. GUINN  
Governor

STATE OF NEVADA  
DEPARTMENT OF HUMAN RESOURCES  
**DIVISION OF HEALTH CARE FINANCING AND POLICY**  
NEVADA MEDICAID

MICHAEL J. WILLDEN  
Director

CHARLES DUARTE  
Administrator

## NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy ("DHCFP"), Pharmaceutical and Therapy Committee, will conduct a public meeting on **March 25, 2004** beginning at **1:00 p.m.** at the following location:

**CARSON CITY**  
**401 South Carson Street**  
**Room 2135**  
**Carson City**

**LAS VEGAS**  
**555 E. Washington Avenue**  
**Room 4406**  
**Las Vegas**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-687-8228 or toll free at: 1-800-992-0900, ext. 43605 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

**Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.**

**Public comment may be limited to 5 minutes per person at the discretion of the Chairperson.**

### AGENDA

- I. Call to Order and Roll Call
- II. \*Approval of February 26<sup>th</sup> meeting minutes
- III. Presentation of DHCFP's recommendations for a Preferred Drug List (PDL), based on Committee actions taken during the February Meeting.
- IV. \*Approval of Drugs for PDL inclusion from February Drug Class Reviews
  - A. Angiotensin Converting Enzyme Inhibitors (ACEI's) and Combinations
  - B. Angiotensin II Receptor Blocker (ARB's) and Combinations
  - C. Gastrointestinal Agents
    1. Proton Pump Inhibitors (PPI's)
    2. Histamine-Two Receptor Antagonists (H2RA's)
  - D. Bisphosphonates
- V. Public comment on March drug class reviews, items VI, VIII, X, XII.
- VI. Presentation from FHSC on drug class reviews:
  - A. Glaucoma Agents
    1. Alpha 2 Adrenergic Agents
    2. Beta Blockers
    3. Carbonic Anhydrase Inhibitors
    4. Prostaglandin Agonists
- VII. \*Committee Discussion and Action for Agenda Item VI
  - A. Discussion and Approval of Clinical/Therapeutic Equivalency of Agents in Each Class
  - B. Discussion and Adoption of Exclusions/exceptions for certain patient groups
  - C. Discussion and Adoption of Clinical Criteria for Prior Authorization

1100 E. William Street, Suite 102, Carson City, Nevada 89701  
(775) 684-3600

- VIII. Presentation from FHSC on drug class reviews:
  - A. Agents in the Treatment of Hepatitis
    - 1. Pegylated Interferons
    - 2. Ribavirins
- IX. \*Committee Discussion and Action for Agenda Item VIII
  - A. Discussion and Approval of Clinical/Therapeutic Equivalency of Agents in Each Class
  - B. Discussion and Adoption of Exclusions/exceptions for certain patient groups
  - C. Discussion and Adoption of Clinical Criteria for Prior Authorization
- X. Presentation from FHSC on Drug class reviews:
  - A. Low-Sedating Antihistamines and Combinations
- XI. \*Committee Discussion and Action for Agenda Item X
  - A. Discussion and Approval of Clinical/Therapeutic Equivalency of Agents in Each Class
  - B. Discussion and Adoption of Exclusions/exceptions for certain patient groups
  - C. Discussion and Adoption of Clinical Criteria for Prior Authorization
- XII. Presentation from FHSC on Drug class reviews:
  - A. Beta Blockers- Oral Agents
- XIII. \*Committee Discussion and Action for Agenda Item XII
  - A. Discussion and Approval of Clinical/Therapeutic Equivalency of Agents in Each Class
  - B. Discussion and Adoption of Exclusions/exceptions for certain patient groups
  - C. Discussion and Adoption of Clinical Criteria for Prior Authorization
- XIV. Recess
- XV. Presentation of DHCFP's recommendations of drugs to be included on a PDL based on the Committee's actions on items VII, IX, XI, XIII.
- XVI. \* Approval of drugs to be included on a PDL based on the Committee's actions on items VII, IX, XI, XIII.
  - A. Glaucoma Agents
    - 5. Alpha 2 Adrenergic Agents
    - 6. Beta Blockers
    - 7. Carbonic Anhydrase Inhibitors
    - 8. Prostaglandin Agonists
  - B. Agents in the Treatment of Hepatitis
    - 1. Pegylated Interferons
    - 2. Ribavirins
  - C. Low-Sedating Antihistamines and Combinations
  - D. Beta Blockers- Oral Agents
- XVII. Public Comment
- XVIII. \*Adjournment

**\* Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

**Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site ([dhcftp@state.nv.us](mailto:dhcftp@state.nv.us)).**

**Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m. or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.**

**All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.**